IP Library Granted Patent US 7,214,808
Granted Patent B2
US 7,214,808 · App. 10/416,029 · Granted May 8, 2007

Method for the production of 4-(17α-substituted-3-oxoestra-4,9-dien-11β-yl)benzaldehyde-(1E)-oximes

Assignee: Schering AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,214,808
App. No.
10/416,029
Granted
May 8, 2007
Kind
B2
Abstract

The invention relates to a method for the production of 4-(17α substituted 3-oxoestra-4,9-dien-11β-yl)benzaldehyd-(1E or 1Z)-oximes of general formula (I), where R 1 ═H, C 1-6 alkyl or a C n F 2n+1 group; R 2 ═C 1-4 alkyl, X=E- or Z-OH; and Y═O—C 1-6 alkyl, S—C 1-6 alkyl or O—CH 2 C n F 2n+1 , where n=1, 2 or 3, which produces the target compounds of formula (I) with high yield and selectivity.

Claims (27)

1. A process for the production of 4-(17α-substituted-3-oxoestra-4,9-dien-11β-yl)benzaldehyde-(1E or 1Z)-oximes of formula (I),

in which R 1 means a hydrogen atom, a C 1-6 -alkyl radical or a C n F 2n+1 radical, R 2 means a C 1-4 -alkyl radical or trifluoromethyl, X means an OH group in E- or Z-position, and Y means an OC 1-6 -alkyl group, an SC 1-6 -alkyl group or an OCH 2 C n F 2n+1 group, whereby n is 1, 2 or 3, characterized in that a 3,3-dimethoxy-5α,10α-epoxy-estr-9(11)-en-17-one of formula (II)

in which R 2 has the above-indicated meaning, is converted with an active methylene reagent in an inert solvent into a 5α,10α-epoxy-17(S)-spiroepoxide of formula (IX)

in which R 2 has the above-indicated meaning, which, after regio- and stereoselective cleavage of the 17-spiroepoxy group by alkali or alkaline-earth alcoholate, by alkylmercaptans in the presence of alkali hydroxides or potassium-tert-butanolate, by direct cleavage with alkali mercaptides or with perfluoroalkyl alcohols in the presence of alkali in an inert solvent, is opened to a 17α-substituted compound of formula (X)

in which R 1 represents a hydrogen atom, Y means an OC 1-6 -alkyl group, an SC 1-6 -alkyl group or an OCH 2 C n F 2n+1 group, whereby n is 1, 2 or 3, and R 2 has the above-indicated meaning, which optionally is converted by reaction of the 17β-hydroxyl group with alkyl halides or haloalkyl fluorides in the presence of strong bases in an inert solvent into the 17β-ethers or 17β-fluoroalkyl ethers of formula (X), in which R 1 is a C 1-6 -alkyl radical or a C n F 2n+1 radical, whereby n is 1, 2 or 3, and R 2 and Y have the above-indicated meanings, which is reacted with a 4-bromobenzaldehyde ketal, magnesium and Cu(I)Cl at temperatures of between −35° C. and room temperature to form the corresponding 3,3-dimethoxy-5α-hydroxy-17α-CH 2 Y-11β-benzaldehyde ketal of formula (XI)

in which R 1 is a hydrogen atom, a C 1-6 alkyl radical or a C n F 2n+1 radical, whereby n is 1, 2 or 3, R 2 and Y have the above-indicated meanings, and R 3 stands for a methyl radical or an ethylidene group, which is converted by acid hydrolysis of the protective groups into an 11β-benzaldehyde derivative of formula (XII),

in which R 1 , R 2 and Y have the above-indicated meanings, and the aldehyde function is converted selectively by hydroxylammonium salts into a mixture of E/Z-benzaldoximes of formula (I),

in which X means an OH group in E- or Z-position.

2. The process according to claim 1 , additionally comprising separating the mixture of the E/Z-benzaldoximes of formula (I) by recrystallization or by chromatography into the individual components.

3. The process according to claim 1 , wherein R 1 means a C 1-3 -alkyl radical.

4. The process according to claim 1 , wherein R 2 means a C 1-3 -alkyl radical.

5. The process according to claim 1 , wherein Y means an OC 1-3 -alkyl radical or an SC 1-3 -alkyl radical.

6. The process according to claim 3 , wherein the compounds

4-[17β-Hydroxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-oxime,

4-[17β-Hydroxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1Z-oxime,

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-oxime,

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien- 11β-yl]benzaldehyde-1Z-oxime,

4-[17-Ethoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-oxime,

4-[17β-Hydroxy-17α-(ethoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-oxime,

4-[17β-Methoxy-17α-(ethoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-oxime,

4-[17β-Hydroxy-17α-(isopropyloxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-oxime,

4-[17β-Methoxy-17α-(isopropyloxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-oxime,

4-[17β-Hydroxy-17α-(ethylthiomethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-oxime or

4-{17β-Hydroxy-17α-(1,1,1-trifluoroethoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-oxime are produced.

7. The process according to claim 3 , wherein R 1 means a methyl or trifluromethyl group.

8. The process according to claim 4 , wherein R 2 means a methyl or trifluromethyl group.

9. The process according to claim 5 , wherein Y means a methoxy, ethoxy, isoproxy, methylthio, ethylthio or triofluroethoxymethyl group.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2025
From: XIAMEN INNO. TECHNOLOGY CO., LTD.
To: XIAMEN JASLEN SANITARY WARE CO.,LTD
Reel/Frame 073056/0196 →
CHANGE OF NAME Recorded May 17, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030434/0232 →
CHANGE OF NAME Recorded May 17, 2013
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030442/0400 →
CHANGE OF NAME Recorded May 17, 2013
From: SCHERING AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030452/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2003
From: SCHUBERT, GERD; RING, SVEN; ERHART, BERND
To: SCHERING AG
Reel/Frame 014592/0302 →
Priority Claims (1)
DE 100 56 676 · Nov 10, 2000 · national
Continuity (1)
Related Publication 20040053905A1 · Mar 18, 2004